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ARTICLE
Classiﬁcation of Human Chromosome 21 Gene-Expression
Variations in Down Syndrome: Impact on Disease Phenotypes
E. Aı¨t Yahya-Graison, J. Aubert, L. Dauphinot, I. Rivals, M. Prieur, G. Golﬁer, J. Rossier,
L. Personnaz, N. Cre´au, H. Ble´haut, S. Robin, J. M. Delabar, and M.-C. Potier
Down syndrome caused by chromosome 21 trisomy is the most common genetic cause of mental retardation in humans.
Disruption of the phenotype is thought to be the result of gene-dosage imbalance. Variations in chromosome 21 gene
expression in Down syndrome were analyzed in lymphoblastoid cells derived from patients and control individuals. Of
the 359 genes and predictions displayed on a speciﬁcally designed high-content chromosome 21 microarray, one-third
were expressed in lymphoblastoid cells. We performed a mixed-model analysis of variance to ﬁnd genes that are differ-
entially expressed in Down syndrome independent of sex and interindividual variations. In addition, we identiﬁed genes
with variations between Down syndrome and control samples that were signiﬁcantly different from the gene-dosage
effect (1.5). Microarray data were validated by quantitative polymerase chain reaction.We found that 29%of the expressed
chromosome 21 transcripts are overexpressed in Down syndrome and correspond to either genes or open reading frames.
Among these, 22% are increased proportional to the gene-dosage effect, and 7% are ampliﬁed. The other 71% of expressed
sequences are either compensated (56%, with a large proportion of predicted genes and antisense transcripts) or highly
variable among individuals (15%). Thus, most of the chromosome 21 transcripts are compensated for the gene-dosage
effect. Overexpressed genes are likely to be involved in the Down syndrome phenotype, in contrast to the compensated
genes. Highly variable genes could account for phenotypic variations observed in patients. Finally, we show that alter-
native transcripts belonging to the same gene are similarly regulated inDown syndrome but sense and antisense transcripts
are not.
From the Neurobiologie et Diversite´ Cellulaire, Unite´ Mixte de Recherche 7637 du Centre National de la Recherche Scientiﬁque et de l’Ecole Supe´rieure
de Physique et de Chimie Industrielles de la Ville de Paris (E.A.Y.-G.; L.D.; G.G.; J.R.; M.-C.P.), Universite´ Paris Diderot-Paris (E.A.Y.-G.; N.C.; J.M.D.),
Unite´ Mixte de Recherche de l’Ecole Nationale du Ge´nie Rural, des Eaux et des Foreˆts, de l’Institut National Agronomique Paris-Grignon et de l’Institut
National de la Recherche Agronomique (J.A.; S.R.), Equipe de Statistique Applique´e (I.R.; L.P.), Service de Cytoge´ne´tique, Hoˆpital Necker Enfants Malades
(M.P.), and Institut Je´roˆme Lejeune (H.B.), Paris
Received March 13, 2007; accepted for publication May 21, 2007; electronically published July 19, 2007.
Address for correspondence and reprints: Dr. M.-C. Potier, Neurobiologie et Diversite´ Cellulaire, CNRS UMR 7637, ESPCI, 10 rue Vauquelin, 75005
Paris, France. E-mail: marie-claude.potier@espci.fr
Am. J. Hum. Genet. 2007;81:475–491.  2007 by The American Society of Human Genetics. All rights reserved. 0002-9297/2007/8103-0006$15.00
DOI: 10.1086/520000
Down syndrome (DS [MIM #190685]) results from the
triplication of chromosome 21 and is the most common
genetic cause of mental retardation in humans, occurring
in ∼1 in 800 newborns. The phenotype of DS is charac-
terized by 180 clinical features, including cognitive im-
pairments, muscle hypotonia, short stature, facial dys-
morphisms, congenital heart disease, and several other
anomalies.1 These clinical features can vary considerably
in number and in severity,2 and certain abnormalities,
such as acute megakaryoblastic leukemia and Hirsch-
sprung disease, occur at higher frequencies in patients
with DS than in the general population.
Trisomy 21 has been known to be the cause of DS since
1959, when Lejeune and colleagues demonstrated the
presence in three copies of chromosome 21 in persons
with DS.3 The phenotype of DS is thus thought to be the
result of gene-dosage imbalance. However, the molecular
mechanisms by which such dosage imbalance causes ab-
normalities remain poorly understood. Two different hy-
potheses have been proposed to explain the phenotype
of DS: “developmental instability” (loss of chromosomal
balance) and “gene-dosage effect.” According to the de-
velopmental instability hypothesis, the presence of a su-
pernumerary chromosome globally disturbs the correct
balance of gene expression in DS cells during develop-
ment.4,5 However, this hypothesis is weakened by the fact
that other autosomal trisomy syndromes do not lead to
the same clinical pattern.6 Moreover, correlations between
genotype and phenotype in patients with partial trisomies
indicate that a restricted region in 21q22.2 is associated
with the main features of DS, including hypotonia, short
stature, facial dysmorphies, and mental retardation.7–9
This DS chromosomal region (DCR) supports the alter-
native gene dosage–effect hypothesis, which postulates
that the restricted number of genes from chromosome 21
that are overexpressed in patients with segmental triso-
mies contributes to the phenotypic abnormalities.
To determine which hypothesis applies to the etiology
of DS, several gene-expression studies of human DS cells
or tissues have been conducted.10–17 Most of these studies
have shown a global up-regulation of the three-copy genes
mapping to the trisomic chromosome, but the limited
number of studied DS cases restricted the statistical anal-
ysis and did not allow the identiﬁcation of precise gene
deregulation. Moreover, these studies were performed us-
ing a small number of three-copy genes. Several other ex-
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Table 1. Experimental Design
Controls
Men with DS Women with DS
1 2 3 4 5 6 7 8 9 10
Men:
11 1 1 1 1 1 1
12 1 1 1 1
13 1 1 1 1 1 1
14 1 1 1 1
Women:
15 1 1
16 1 1
17 1 1 1 1
18 1 1 1 1
19 1 1
20 1 1
21 1 1 1 1
NOTE.—Microarray experiments were performed using LCLs from indi-
viduals with DS and control individuals in accordance with a mixed model
(see the “Material and Methods” section). Each “1” indicates one ex-
periment. “1” means that DS and control samples were labeled with
Cy5 and Cy3, respectively. “1” means that DS and control samples were
labeled with Cy3 and Cy5, respectively.
Table 2. List of Oligonucleotide Primers
Used in the QPCR Experiments
Primer
Sequence
(5′r3′)
CHAF1B_UP CCATCATATGGGATGTCAGCAA
CHAF1B_LOW CTTCATGCTGTCGTCGTGAAAC
CSTB_UP GCCACCGCCGAGACCCAGCA
CSTB_LOW TGGCTTTGTTGGTCTGGTAG
DSCR1_UP GCACAAGGACATTTGGGACT
DSCR1_LOW TTGCTGCTGTTTTCACAACC
DYRK1A_UP ATCCGACGCACCAGCATC
DYRK1A_LOW AATTGTAGACCCTTGGCCTGGT
GART_UP CTGGGATTGTTGGGAACCTGAG
GART_LOW ACCAAAGCAGGGAAGTCTGCAC
H2BFS_UP CAGAAGAAGGACGGCAGGAA
H2BFS_LOW GAAGCCTCACCTGCGATGCG
MX1_UP GCCAGTATGAGGAGAAGGTGCG
MX1_LOW GTTTCAGCACCAGCGGGCATCT
SNF1LK_UP GCCGCTTCCGCATCCCCTTCTT
SNF1LK_LOW CTCATCGTAGTCGCCCAGGTTG
SOD1_long_UP TCGCCCAATAAACATTCCCTTG
SOD1_long_LOW AAGTCTGGCAAAATACAGGTCATTG
STCH_UP GGACGTGGCCTTTCTGATAA
STCH_LOW CTTGACGGATCCGAGGAATA
TMEM1_UP CGTGCAGGAACTGAAGCTCTTA
TMEM1_LOW TCTGAGCTGTGTTGGCTGTTTC
L13852_UP CTCCAATCTCAGCCGTCAGT
L13852_LOW AGCCACACCATCCACACGGG
AB000468_UP CAAGAAAGCGTCGTGGTGGA
AB000468_LOW ATCGTCACTGCTCACCACAC
periments have been done on animal models of DS with
a greater number of chromosome 21 gene orthologs by
use of microarray and quantitative PCR experiments.18–21
In these studies, the three-copy genes were overexpressed,
with a mean ratio of 1.5, which is proportional to the
gene-dosage imbalance. However, some of these tripli-
cated genes appeared to escape the “1.5-fold rule.” Yet,
these animal models are not trisomic for all chromosome
21 orthologs. Thus, a comprehensive classiﬁcation of all
human genes on chromosome 21, according to their level
of expression in DS, does not yet exist.
The goal of the present study was to ﬁll this knowledge
gap and to ﬁnd the genes that are likely to be involved
in DS phenotypes through their transcriptional dysregu-
lation.22 For this purpose, we designed an oligonucleotide
microarray containing all chromosome 21 genes, ORFs,
antisense transcripts, and predicted genes listed in the
most common databases (NCBI Gene Database, Eleanor
Roosevelt Institute, and Max Planck Institute), except for
the 53 genes of the keratin-associated protein cluster.Gene
expression was measured on lymphoblastoid cell lines
(LCLs) from 10 patients with DS and 11 control individ-
uals. LCLs are easy to obtain and are widely used to study
genotype-phenotype correlations.23 To our knowledge,
this is the most comprehensive study so far that has been
done using triplicated genes in DS human cells. In addi-
tion, we analyzed data with a mixed-model analysis of
variance, to ﬁnd genes that are differentially expressed in
DS independent of sex and interindividual variations.Our
data show a global gene dosage–dependent expression of
chromosome 21 genes in LCLs, with no effect of sex. In
addition, by use of our data-analysis protocol, chromo-
some 21 genes can now be classiﬁed into four classes: class
I genes are overexpressed with a mean ratio very close to
1.5, proportional to the gene-dosage effect of trisomy 21;
class II genes are overexpressed with ratios signiﬁcantly
11.5, reﬂecting an ampliﬁcation mechanism; class III
genes have ratios signiﬁcantly !1.5, corresponding to
compensated genes; and class IV genes have expression
levels that are highly variable between individuals. This
classiﬁcation should have an impact on the search for
genes that are involved in the DS phenotype.
Material and Methods
Cell Lines and Culture Conditions
LCLs were derived from the B lymphocytes of 10 patients with
DS collected from the cytogenetic service of the hospital Necker
Enfants Malades and the Institut Je´roˆme Lejeune. Parents of pa-
tients from the Institut Je´roˆme Lejeune gave their informed con-
sent, and the French biomedical ethics committee gave its ap-
proval for this study (Comite´ de Protection des Personnes dans
la Recherche Biome´dicale number 03025). Written informed con-
sent was obtained from the participants or from their families by
the cytogenetic service of Hoˆpital Necker Enfants Malades. Cell
lines from 11 control individuals were also obtained with their
written informed consent, for comparison of chromosome 21
gene-expression proﬁles. Culture media consisted of Opti-MEM
with GlutaMax (Invitrogen) supplemented with 5% fetal bovine
serum from a unique batch and 1% penicillin and streptomycin
mix (10,000 U/ml). Cell lines were grown at 37C in humidiﬁed
incubators, in an atmosphere of 5% CO2. Each culture was grown
to at least cells. All cell lines were karyotyped, to conﬁrm660# 10
their trisomic or euploid status and also to verify that immor-
talization by the Epstein-Barr virus (EBV) did not produce any
visible chromosomal rearrangement other than trisomy 21. Cells
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Table 3. HSA21 Oligoarray Content
Putative Expressed
Sequences HSA21 Contenta
HSA21 Oligoarray Content
No. of
Sequencesb
HSA21
Coveragec
(%)
Genes 182 145 82.42
ORFs 93 58 62.37
Predictions Not represented 118d NA
Antisense transcripts Only 1 represented 18 NA
a NCBI Gene Database build 36.2 was used to estimate HSA21 gene content. Only
current sequences were considered, with the exception of pseudogenes and hypo-
thetical proteins.
b The number of HSA21 sequences represented by at least one probe on the HSA21
oligoarray.
c The percentage of HSA21 sequences currently annotated in NCBI Gene Database
that are represented on the microarray. NA p not available.
d Of the 118, 20 are represented with their reverse sequence.
Table 4. Classiﬁcation of HSA21 Genes by Statistical
Analysis
DS/Control Ratio
Class by DS/Control Ratio
Not Signiﬁcantly
Different from 1
Signiﬁcantly
Different from 1
Signiﬁcantly 11.5 … II
Not signiﬁcantly
different from 1.5 IV I
Signiﬁcantly !1.5 III …
were harvested by centrifugation, were washed in 5 ml PBS, fol-
lowed by another centrifugation, and were stored at 80C.
Human Chromosome 21 (HSA21) Oligoarray
A dedicated oligonucleotide microarray—named “HSA21 oli-
goarray,” containing 664 50-mer amino-modiﬁed oligonucleo-
tides representing 145 genes, 58 ORFs, 118 predictions (20 of
them represented in both orientations), and 18 antisense tran-
scripts assigned to chromosome 21—was used in the present
study. Predictions represented on the array included cDNAs and
exons from the CBR-ERG region on 21q deduced from cDNA iso-
lation and exon-trapping experiments8 and gene or exon predic-
tions produced from in silico analysis of the complete sequence
of human chromosome 21.24 Nonredundant transcript sequences
and antisense transcripts were also included in this oligoarray.25–
27 Thirty-nine genes assigned to chromosomes other than chro-
mosome 21, represented by 58 oligonucleotides—showing awide
range of expression levels according to UniGene and no varia-
tions between DS and control samples as demonstrated by the
ﬁrst version of the HSA21 oligoarray (data not shown)—were
added for data normalization. All probes present on the array
were designed using the SOL software (G.G., S. Lemoine, A. Bend-
joudi, J.R., S. Lecrom, and M.-C.P., unpublished data). Sequences
were then synthesized by EuroGentec and were spotted onto
CodeLink activated glass slides (Amersham Biosciences) by use of
a MicroGrid II spotter (Biorobotics). Each array contained two
matrices with eight blocks each, in which probes were present in
duplicates so that each oligonucleotide was present in four rep-
licates on each slide.
Experimental Design
The experiment comprised 10 patients with DS (7 men and 3
women) and 11 controls (4 men and 7 women). Samples from
the same individual were used in different hybridizations.
For each gene, we used the linear model
y p mD  S A  F DSijklm i j l m ij
DF  SF  I(DS)   , (1)im jm ijk ijklm
where is the normalized expression of the gene in log2 foryijklm
factor i (DS or control sample), sex is j, patient number is k
( ), dye label is m (m is red, for Cy5, or green, for Cy3)kp 1,…,21
on the HSA21 oligoarray l. The symbols D, S, A, and F represent
the ﬁxed effects due to the disease, sex, array, and ﬂuorochrome,
respectively. For example, D represents the modiﬁcations of the
gene expression level due to the disease.A and F are bothnuisance
parameters that account for potential technological biases. DS,
DF, and SF correspond to interacting effects: disease and sex, dis-
ease and ﬂuorochrome, and sex and ﬂuorochrome, respectively.
The symbol I(DS) refers to the patient (nested within disease and
sex) random effect. This last effect accounted for the correlation
between samples used in different hybridizations but collected
from the same patient.
We assumed the independence between all I(DS)ijk and Eijklm.We
also assumed that I(DS)ijk was independent with a distribution
N(0,s2) and that Eijklm was independent with distribution N(0,j
2).
Model (1) can be rewritten under the matrix form
YpXvZUE , (2)
where v is the vector of ﬁxed effects (D, S, A, F, DS, DF, and SF),
U is the vector of I(DS)ijklm, and E is the vector of Eijklm. Y ∼
, where . Y has n rows (n is the total2 2 TN(Xv,S) Sp 2j Id s ZZg g
number of samples) and one column, X is the matrix describing
the status of the patient (disease and sex) from which the sample
was collected. Z has n rows and I columns (I is the total number
of patients) and describes the correspondence between samples
and patients.
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Figure 1. Classiﬁcation of HSA21 genes according to the expression ratio between DS and control LCLs. The sum of classiﬁed genes
is 136 genes minus 2 (C21ORF108 and PRMT2) that appear twice, depending on the oligonucleotide probe considered (see the “Results”
section for details).
On each array l,we actually observed the differential expression
(red signal minus green signal)
y p y  y p (D D ) (S  S )′ ′ ′ ′ ′ ′ ′ ′ ′ ′ii jj kk lmm ijklm i j k lm i i j j
(DS DS ) (F  F )′ ′ ′ij i j m m
(DF DF ) (SF  SF )′ ′ ′ ′im im im im
[I(DS)  I(DS) ] (   ) . (3)′ ′ ′ ′ ′ ′ ′ ′ijk i j k ijklm i j k lm
This model can be rewritten under another matrix, D, describing
the comparisons performed on each array. This matrix had L rows
(L is the total number of arrays) and n columns. The lth row of
D was zero except for the value 1 in the column corresponding
to the sample labeled in red and1 in the column corresponding
to the sample labeled in green. The model for the differential
expression was obtained by multiplying all terms of equation (2)
by D:
DYp DXvDZUDE .
The vector of differential expression DY has distribution
N(DXv,DSDT).
The experimental design was deﬁned by the three matrices X,
Z, and D. X and Z basically depend on the number of samples
for each patient. Because the microarrays used were two-color
assays, the total number of samples was twice the number of
slides.
The important remaining choice was the comparison to be
made—that is, the choice of D. Consideration of the differential
expression between two patients analyzed on the same array elim-
inated the array effect and the corresponding constants. We were
not interested in other technical effects, such as ﬂuorochrome or
interactions of ﬂuorochrome with other effects. To eliminateDFim
and SFjm effects, we proposed a balanced design for the ﬂuoro-
chrome effect. Finally, data were normalized across genes, to re-
move the dye effect .Fm
The last criterion was D—the precision of the estimated effects
(gathered into the vector ). According to the mixed linear modelˆv
theory, this precision is given by its variance matrix,
T T T 1 1ˆV(v )p [D X (DSD ) DX] ,A
which depends on D and the ratio j2/s2. The diagonal contained
all the information about the quality of the estimates. It gave the
variance of the estimates of all effects of interest to , , andD Si j
. This matrix was the ultimate tool for comparing the designs.DSij
We calculated the variance of the disease effect (which is of
primary interest) and the determinant of the variance covariance
matrix (which gave a global measure of the precision of the es-
timates) for a certain number of designs D. To do that, we used
a value given a priori for the ratio j2/s2 equal to 2.
We ﬁnally chose a design involving 40 arrays. Each patient
appeared in two to eight different experiments, and samples from
the same patient were marked the same number of times with
each ﬂuorescent dye (Cy3 or Cy5). On each array, a DS LCL and
a control LCL were compared, to increase the precision of the
disease effect. Ten arrays compared (i) a man with DS and an
unaffected man, (ii) a female with DS and an unaffected female,
(iii) a man with DS and an unaffected female, or (iv) a female
with DS and an unaffected male. The design is described in table
1.
mRNA Extraction, HSA21 Oligoarray Hybridization, Data
Filtering, and Normalization
mRNA was extracted from frozen individual cell samples by use
of Fast Track 2.0 mRNA Isolation kit (Invitrogen) in accordance
with the manufacturer’s instructions. To eliminate DNA contam-
ination, the appended DNase protocol of RNeasy mini kit (Qia-
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gen) was used in accordance with the manufacturer’s protocol.
Samples were further tested for purity and quantity with RNA
6000 NanoChips by use of the Agilent 2100 Bioanalyzer (Agilent
Technologies). By use of the Reverse-iT RTase Blend kit (ABGene),
2 mg of mRNA was converted into Cy3- or Cy5-labeled cDNA by
incorporation of ﬂuorescent dUTP (Amersham). Labeled targets
were then puriﬁed on Qiaquick columns in accordance with the
manufacturer’s protocol (Qiagen). Hybridization of sample pairs
on HSA21 oligoarrays (one DS sample and one control sample),
according to the experimental design, was performed using hy-
bridization buffer (50% formamide, 4# saline sodium citrate
[SSC], 0.1% SDS, and 5# Denhart) at 42C overnight. Slides were
washed in 2# SSC and 0.1% SDS three times for 5 min, in 0.2#
SSC for 1 min, and in 0.1# SSC for 2 min. Data were acquired
with GenePix 4000B scanner and by use of the GenePix Pro 6.0
software (Axon). For each array, the raw data comprised the me-
dian feature pixel intensity at wavelengths 635 nm and 532 nm
for Cy5 and Cy3 labeling, respectively. After subtraction of the
background signal, LOWESS normalization28 of the M values cor-
responding to Cy5/Cy3 signal ratios in log2 was applied to all
oligonucleotides representing non-HSA21 genes and was used to
calculate a correction factor applied to M values for HSA21 probes
under The R Project for Statistical Computing. Normalized data
from each slide was then ﬁltered using two criteria: (i) for each
oligonucleotide, at least two values among the four replicates had
to be available, and (ii) SD of values corresponding to the geo-
metricmean in log2 of Cy3 andCy5 signal intensities (theA value)
had to be !1. Arithmetic means of normalized and ﬁltered M and
A values were calculated for each oligonucleotide and were sub-
mitted to the statistical analysis. All microarray data used in this
study were deposited in the Gene Expression Omnibus (GEO)
database (accession number GSE6408).
Expression Data Analysis: Statistical Testing
Mixed model.—To determine differentially expressed genes for
DS, sex, and DS# sex effects, we performed a mixed-model anal-
ysis of variance according to the experimental design. This
method was chosen to distinguish between interindividual var-
iability and experimental variability.29 We used the mixed pro-
cedure of the SAS software with the restricted maximum likeli-
hood (REML) method of estimation.30 After the ﬁltering and
normalization steps, the number of observations per spot varied
between 8 and 40, which was enough to calculate the variance
for each gene.
We ﬁrst tested the effects of the complete model (3). Since the
sex and DS# sex effects were not signiﬁcant for any gene, these
two effects were dropped from the model. We ﬁnally analyzed
the simpliﬁed model
y p y  y′ ′ ′ ′ ′ ′ii jj kk l ijkl i j k l
p (D D ) [I(DS)  I(DS) ] (   ) .′ ′ ′ ′ ′ ′ ′ ′ ′i i ijk i j k ijklm i j k lm
We deduced raw P values from comparison with 1 under the
null hypothesis and adjusted them by the Benjamini-Hochberg
procedure, which controls the false-discovery rate (FDR).31 We
then analyzed the simpliﬁedmodel by comparisonwith 1.5under
the null hypothesis and adjusted the raw P values by use of the
method described by Storey et al.32
Principal-components analysis (PCA).—Results frommicroarray ex-
periments were obtained as the differential expression between
DS and control samples. M values corresponded to log (DS)2
, and A values to . Forlog (control) [log (DS) log (control)]/22 2 2
each probe p, the mean value of its expression (in log2) in DS cell
lines and in controls could thus be expressed as
k1 Mpi kE p A  for ip 1–10 (DS)p p( )N 2kSii ,k1 Mp{ }i kE p A  for ip 11–21 (controls)p p( )N 2kSii
where i denoted the index of the individual, Si the set of slides
on which all samples from the individual i have been hybridized,
and Ni the size of this set. Since the overall expression level of
the genes of one individual varied from one slide to another and
to avoid normalization across slides, we made the simpliﬁcation
and reconstructed relative mean values of expression EkA p 0p
for each individual as
k1 MpiE p for ip 1–10 (DS)p ( )N 2kSii .k1 Mp{ }iE p  for ip 11–21 (controls)p ( )N 2kSii
PCA of chromosome 21 genes and genes mapping to other
chromosomes was performed separately using E values deduced
from all expressed chromosome 21 probes and all expressed non–
chromosome 21 probes, respectively.
PCR Experiments
To validate expression ratios between DS and control samples
obtained from HSA21 oligoarray data, 100 ng of mRNA was re-
verse transcribed into cDNA by use of Reverse-iT RTase Blend kit
(ABgene). Quantitative real-time PCR (QPCR) on diluted cDNA
was conducted in the presence of 0.6 mM of each speciﬁc primer
(designed by Primer3 software) and 1# Quantitect SYBR Green
PCR master mix (Qiagen) containing 2.5 mM MgCl2, Hotstart Taq
polymerase, dNTP mix, and the ﬂuorescent dye SYBR Green I.
QPCR experiments were performed in a Lightcycler system
(Roche Molecular Biochemicals) on 11 HSA21 genes: CHAF1B,
CSTB, DSCR1, DYRK1A, GART, H2BFS,MX1, SNF1LK, SOD1,STCH,
and TMEM1. The ubiquitin-activating enzyme E1 (NCBI Entrez
accession number L13852) mRNAmapping to HSA3 and the zinc-
ﬁnger protein (NCBI Entrez accession number AB000468) mRNA
mapping to HSA4 were used as endogenous control genes, as
described by Janel et al.33 For each sample, the mean cycle thresh-
old value, Ct, was corrected by subtracting the mean of the Ct
obtained with the two reference genes. PCR primers are listed in
table 2.
Results
Design of a Comprehensive HSA21 Oligoarray
The HSA21 oligoarray was designed for the exhaustive
study of human chromosome 21 gene expression in DS.
This microarray contained 664 sequences representing
145 genes, 58 ORFs, 118 predictions (plus the reverse se-
quences for 20 of them), and 18 antisense transcripts, al-
lowing expression analysis of all putative genes mapping
to chromosome 21 and related to DS. To increase the
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Table 5. List of Genes Classiﬁed According to Their Expression in DS LCLs
Gene Symbol
GenBank
Accession
Number Ratio A M Var(M) Classa
as-TTC3 BF979681.2 1.56 9.07 .64 .64 I
C21orf108 (exon 39) AF231919.1 1.30 7.84 .38 .18 I
C21orf33 BI824121.1 1.52 10.54 .60 .20 I
C21orf59 AF282851.1 1.35 9.61 .44 .21 I
C21orf66 AY033903.1 1.51 9.50 .59 .12 I
C21orf7 AY171599.2 1.43 8.00 .52 .49 I
C21orf91 BC015468.2 1.59 9.50 .67 .26 I
CBS AF042836.1 1.61 8.13 .69 .48 I
CCT8 BC095470.1 1.65 12.64 .72 .32 I
CRYZL1 BC033023.2 1.52 9.45 .60 .12 I
DONSON AF232673.1 1.42 9.73 .50 .11 I
DYRK1A D86550.1 1.41 10.20 .49 .17 I
HMGN1 M21339.1 1.38 11.82 .46 .10 I
IFNAR1 AY654286.1 1.47 8.10 .56 .18 I
IFNAR2 BC013156.1 1.67 8.38 .74 .14 I
IFNGR2 AY644470.1 1.45 10.35 .54 .24 I
IL10RB BT009777.1 1.66 10.18 .73 .21 I
ITGB2 BC005861.2 1.61 11.34 .68 .40 I
MCM3AP AY590469.1 1.45 11.69 .54 .19 I
MRPL39 AF109357.1 1.47 9.82 .55 .15 I
PFKL X15573.1 1.50 12.44 .58 .23 I
PIGP AF216305.1 1.60 8.14 .68 .25 I
PTTG1IP NM_004339.2 1.52 9.89 .60 .20 I
SFRS15 AF023142.1 1.39 10.42 .47 .14 I
SLC5A3 L38500.2 1.57 8.92 .66 .18 I
SON AY026895.1 1.51 12.64 .60 .14 I
SUMO3 BC008420.1 1.41 10.82 .50 .10 I
USP16 AY333928.1 1.46 9.94 .54 .10 I
USP25 AF170562.1 1.58 9.93 .66 .10 I
ZNF294 NM_015565.1 1.51 8.77 .60 .11 I
BTG3 D64110.1 1.82 10.63 .86 .21 II
C21orf57 AY040875.1 1.74 9.49 .80 .28 II
MRPS6 AB049942.1 1.64 10.26 .72 .13 II
PDXK AY303972.1 1.71 10.06 .77 .23 II
SAMSN1 AF222927.1 2.27 10.47 1.18 .72 II
SLC37A1 AF311320.1 1.72 9.33 .78 .32 II
SNF1LK AB047786.1 2.14 9.47 1.10 1.15 II
STCH U04735.1 1.97 9.86 .98 .42 II
TTC3 D84296.1 1.79 10.59 .84 .20 II
aa071193 AA071193.1 .97 7.34 .05 .48 III
AIRE AB006682.1 .82 7.28 .28 .29 III
AL041783 AL041783.1 1.06 7.10 .09 .36 III
as-C21orf56 BC084577.1 1.07 11.75 .10 .08 III
as-KIAA0179 AA425659.1 1.16 8.08 .22 .67 III
ATP5J BC001178.1 1.35 7.99 .44 .11 III
B184 AL109967.2 1.06 9.10 .08 .62 III
B27 inverse AP000034.1 .83 8.40 .27 .31 III
C21orf108 (exon 26) AF231919.1 1.09 8.86 .13 .09 III
C21orf12 AP001705.1 .97 7.49 .05 .72 III
C21orf2 NM_004928.1 1.30 8.80 .38 .14 III
C21orf21 AA969880 1.16 7.33 .22 .28 III
C21orf25 AB047784.1 1.19 8.61 .25 .31 III
C21orf29 AJ487962.1 .98 7.27 .03 .22 III
C21orf34 AF486622.1 .93 8.17 .11 .28 III
C21orf42 AY035383.1 1.14 10.05 .19 .22 III
C21orf45 AF387845.1 1.23 9.39 .30 .12 III
C21orf49 BC117399.1 1.14 7.80 .19 .32 III
C21orf51 AY081144.1 1.26 9.47 .33 .09 III
C21orf54 AA934973.1 1.01 7.26 .01 .38 III
C21orf58 BC028934.1 1.11 7.73 .15 .21 III
C21orf6 BC017912.1 1.20 9.63 .26 .22 III
CHAF1B U20980.1 1.29 8.35 .37 .13 III
CLIC6 AF448438.1 .74 9.26 .43 .98 III
(continued)
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Table 5. (continued)
Gene Symbol
GenBank
Accession
Number Ratio A M Var(M) Classa
CXADR AF200465.1 .90 8.16 .15 .32 III
D21S2056E U79775.1 1.33 10.55 .41 .18 III
DCR1-17.0 AJ001875.1 1.13 7.16 .17 .71 III
DCR1-19.0 AJ001906.1 .94 7.13 .09 .19 III
DCR1-20.0-reverse AJ001893.1 .95 7.14 .07 .36 III
DCR1-25.0-reverse AJ001905.1 .96 7.34 .06 .31 III
DCR1-7.0 AJ001861.1 1.09 7.48 .12 .27 III
DCR1-7.0-reverse AJ001861.1 1.21 7.13 .28 .28 III
DCR1-8.0 AJ001862.1 .98 7.58 .03 .42 III
DCR1-8.0-reverse AJ001862.1 1.00 8.61 .00 .20 III
DSCAM_Intronic_Model BG221591.1 1.21 8.39 .28 1.39 III
DSCR1 AY325903.1 .93 7.13 .10 .74 III
DSCR10 AB066291.1 .95 8.60 .07 .25 III
DSCR2 AY463963.1 1.25 10.98 .32 .18 III
DSCR3 D87343.1 1.40 10.09 .48 .12 III
DSCR6 AB037158.1 1.03 7.37 .04 .41 III
DSCR9 BC066653.1 1.05 7.69 .07 .28 III
ETS2 J04102.1 1.40 7.18 .49 .43 III
GABPA BC035031.2 1.40 8.88 .49 .08 III
GART X54199.1 1.17 9.55 .23 .15 III
H2BFS AB041017.1 1.13 13.19 .17 .57 III
HLCS AB063285.1 1.32 8.48 .40 .18 III
ICOSLG AF289028.1 1.23 9.99 .30 .28 III
JAM2 AY016009.1 .98 8.07 .03 .82 III
KCNE1 BC046224.1 1.12 7.18 .16 .40 III
KIAA0179 D80001.1 1.21 10.15 .28 .24 III
MORC3 BC094779.1 1.34 8.51 .42 .15 III
n74695 N74695 .93 9.83 .10 .18 III
PKNOX1 AY196965.1 1.04 7.81 .05 .12 III
POFUT2 NM_015227.3 1.35 7.46 .43 .49 III
PRED21 AP001693.1 .95 7.75 .07 .66 III
PRED24 AP001695.1 1.00 7.41 .00 .65 III
PRED41 AP001726.1 .93 7.15 .11 .64 III
PRED59 AL163301.2 .94 7.94 .09 .17 III
PRED63 AP001759.1 .99 7.56 .01 .18 III
PRED65 AL163202.2 1.06 7.10 .08 .25 III
PRMT2 (exon 5/6) U80213.1 1.34 8.67 .42 .14 III
PWP2H U56085.1 1.34 9.43 .42 .11 III
RUNX1 D43968.1 .85 7.91 .23 .76 III
SETD4 AF391112.1 1.09 9.24 .13 .21 III
SH3BGR X93498.1 1.07 7.19 .10 .83 III
SLC19A1 AF004354.1 1.20 7.80 .26 .14 III
SOD1b AY835629.1 1.15 9.55 .21 .21 III
SYNJ1 AF009039.1 1.29 8.07 .37 .13 III
TFF3 BC017859.1 .97 8.00 .04 .46 III
TMEM1 BC101728.1 1.27 10.52 .34 .14 III
TMEM50B AF045606.2 1.38 10.07 .46 .20 III
U2AF1 M96982.1 1.27 12.15 .35 .06 III
UBASH3A AJ277750.1 1.13 7.32 .17 .21 III
UBE2G2 AF032456.1 1.17 12.08 .22 .18 III
W90635 W90635.1 1.09 7.39 .12 .45 III
WRB BC012415.1 1.21 8.21 .27 .29 III
ZNF295 BC063290.1 1.19 8.78 .25 .27 III
ABCG1 AY048757.1 1.25 8.11 .32 .79 IV
ADARB1 AY135659.1 1.26 7.28 .34 3.06 IV
as-MCM3AP-C21orf85 AW163084.1 1.41 7.71 .50 1.02 IV
BRWD1 AB080586.1 1.44 9.14 .53 .38 IV
C21orf22 AY040089.1 1.27 7.56 .34 .88 IV
C21orf8 AA843704.1 1.09 7.55 .12 1.32 IV
CBR1 AB124848.1 1.47 8.20 .55 .76 IV
COL6A1 NM_001848.2 1.60 7.34 .68 .62 IV
CSTB AF208234.1 1.35 12.79 .43 .38 IV
(continued)
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Table 5. (continued)
Gene Symbol
GenBank
Accession
Number Ratio A M Var(M) Classa
DCR1-12.0 AJ001868.1 1.28 7.37 .36 .76 IV
DCR1-12.0-reverse AJ001868.1 1.44 8.01 .53 1.06 IV
DCR1-13.0 AJ001869.1 1.25 9.20 .32 1.26 IV
DCR1-13.0-reverse AJ001869.1 1.14 8.98 .19 .91 IV
DCR1-15.0 AJ001872.1 1.28 7.08 .36 1.00 IV
DSCR4 DQ179113.1 1.32 7.41 .40 .53 IV
MX1 AF135187.1 1.49 13.61 .58 .67 IV
MX2 M30818.1 1.33 11.94 .41 .48 IV
PRDM15 AF426259.1 1.38 8.88 .47 .51 IV
PRMT2 (exon 8/9) U80213.1 1.46 8.73 .55 .58 IV
TRPM2 AY603182.1 1.08 7.50 .11 1.82 IV
NOTE.—The value A corresponds to for the corresponding[log (DS) log (control)]/22 2
gene across the 40 hybridizations, M corresponds to the mean of log (DS)2
for the corresponding gene across the 40 hybridizations, is the var-log (control) Var (M)2
iance of M, and the DS/control ratio is equal to 2M.
a Class I corresponds to genes expressed proportionally to the gene-dosage effect in DS
cell lines, class II contains genes that are ampliﬁed, class III contains genes that are com-
pensated, and class IV contains genes that are highly variable between individuals.
b Oligonucleotide probes mapped to the long isoform of SOD1. See details in the “Discussion”
section.
strength of the results, where possible, at least two probes
per gene were designed (∼80% of the HSA21 oligoarray
content). The description of the HSA21 oligoarray content
according to BLAST results performed on the latest version
of the human genome sequence (NCBI Gene Database
build 36.2) is summarized in table 3. Oligonucleotide se-
quences spotted on the array have been designed on the
basis of four main criteria: speciﬁcity for the represented
sequence, GC content equal to 50%, melting temperature
allowing an optimal match between probe and target at
the hybridization temperature, and no stable predicted
secondary structure.
By use of this new speciﬁc high-content HSA21 oli-
goarray, 40 differential hybridizations comparing DS and
control LCLs were performed. The mean signal intensities
(represented in log2 by the A value) of each array spot
indicated the expression levels of chromosome 21 genes.
A total of 134 genes gave signal intensities above the back-
ground cutoff (mean ).A 1 7
Biological Material from Patients with DS and Control
Individuals
LCLs were obtained after immortalization by EBV of B
lymphocytes collected from blood samples of individuals
with DS and control individuals. To make sure that EBV
transformation did not induce any chromosomal rear-
rangement, all cell lines were karyotyped after immortal-
ization. Cell lines were always maintained in exponential
growth phase. No signiﬁcant difference in cell morphol-
ogy or cell proliferation was observed between DS and
control LCLs.
For three individuals with DS, transcriptome compari-
sons between fresh blood samples and LCLs obtained from
the same individuals were conducted on pangenomic mi-
croarrays.34 From these experiments, no major alteration
of the transcriptome by the EBV transformation could be
detected; only 0.5% of the genes exhibited signiﬁcant dif-
ferential expression ( ) (L.D., E.A.Y.-G., andM.-C.P.,Pp .01
unpublished data).
Experimental Design and Statistical Analysis
The main objective was to detect differentially expressed
genes between DS and control samples, taking into ac-
count the sex of and variability between individuals. The
aim of the experimental design was to adapt to the ex-
perimental constraints of the study (see table 1 and the
“Material and Methods” section). Forty experiments were
thus programmed.
First, a mixed model was constructed to highlight the
effects of DS, sex, and DS # sex and to take into account
the gene-expression variability between individuals. We
used the Benjamini-Hochberg procedure to adjust the P
values obtained and to limit false-positive results due to
multiple testing.31 The FDR was set at 0.05. The list of
signiﬁcant genes was thus expected to contain 5% false-
positive results.
Chromosome 21 genes did not have signiﬁcant P values
when sex or DS and sex combined (DS# sex) were tested.
In other words, chromosome 21 gene expression was not
signiﬁcantly different between men and women. In ad-
dition, DS effects on gene expression were not dependent
on sex. The effects of sex and DS# sex were thus dropped
from the model, and a simpliﬁed mixed model testing the
effects of DS on HSA21 gene expression was ultimately
used. We ﬁrst selected genes that had DS/control ratios
signiﬁcantly different from 1 (FDR 0.05), using the Ben-
jamini-Hochberg procedure.31 Among the 136 expressed
transcripts (134 genes), about half (58) had DS/control
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Figure 2. Distribution of DS/control ratios for class I, II, III,
and IV genes and non-HSA21 reference genes. The plot represents
the minimum and maximum values (whiskers), the ﬁrst and third
quartiles (box), and the median value (midline) of DS/control ratios
for each class of genes.
ratios different from 1 and always 11, indicating that these
genes were signiﬁcantly overexpressed in DS LCLs. Ex-
pression ratios of these 58 genes ranged from 1.25 to 2.27,
with a mean of 1.5, corresponding to the gene-dosage ef-
fect in DS. In parallel, among the 134 expressed genes, we
selected those that deviated from this gene-dosage effect
with a ratio signiﬁcantly different from 1.5. Surprisingly,
the majority of expressed transcripts (86) had DS/control
ratios signiﬁcantly different from 1.5 (FDR 0.05). Because
of this high number, the method described by Storey et
al.32 for adjustment of the FDR had to be applied. Results
showed that 86 genes had DS/control ratios signiﬁcantly
different from 1.5. Of these 86 genes, 9 had DS/control
ratios 11.5, in the range 1.64–2.27, and 77 had DS/control
ratios !1.5, in the range 0.74–1.4.
On the basis of this statistical analysis, we classiﬁed
genes into four categories according to their variation of
expression between DS and control LCLs, as described in
table 4 and represented in ﬁgure 1. Class I contained 30
genes with DS/control ratios signiﬁcantly different from
1 but not signiﬁcantly different from 1.5, in the range
1.3–1.67. Class II contained nine genes that were signiﬁ-
cant in both statistical tests, with DS/control ratios sig-
niﬁcantly different from 1, signiﬁcantly different from1.5,
and 11.5 (range 1.64–2.27). Class III comprised 77 genes
that had DS/control ratios signiﬁcantly different from 1.5
and !1.5 (range 0.74–1.4). The majority of gene predic-
tions and antisense transcripts (77%) belonged to this
class. In addition, gene expression levels of the transcripts
belonging to class III were signiﬁcantly lower than those
belonging to class I ( ) and class II (5Pp 1.32# 10 Pp
). Class IV included the remaining 20 geneswith75.7# 10
DS/control ratios not signiﬁcantly different from 1 or from
1.5, in the range 1.08–1.6. Table 5 gives the complete list
of genes. Distributions (box plots) of DS/control ratios for
each class and for non–chromosome 21 reference genes
are shown in ﬁgure 2.
The goal of this study was also to demonstrate whether
chromosome 21 gene-expression proﬁles could differen-
tiate DS from control samples. We therefore performed
two distinct PCAs on the 134 chromosome 21–expressed
genes and the 39 non–chromosome 21 genes used as ref-
erences (see the “Material and Methods” section). PCA
could clearly distinguish individuals with DS from control
individuals, suggesting that the effects of DS on chro-
mosome 21 gene expression prevails over any other effect,
including biological variability (ﬁg. 3A). In addition, no
distinction could be obtained between individuals with
DS and control individuals when PCA was conducted on
non–chromosome 21 genes (ﬁg. 3B). Non–chromosome
21 genes had a mean DS/control expression ratio of 1 (ﬁg.
2).
Most of the genes present on the HSA21 oligoarraywere
represented by two probes. When the two probes were
found to be expressed, they belonged to the same class,
except forC21ORF108 and PRMT2.ConcerningC21ORF108,
one probe (B1KIAA0539.eri10102_a) mapping to exon
39 ofC21ORF108 belonged to class I (DS/control ratio 1.3).
The other probe (KIAA0539.gff6561_b), mapping to exon
26 of C21ORF108, was in class III (DS/control ratio 1.09).
This difference could result from the existence of two
alternative transcripts containing either exon 26 or ex-
on 39. Similarly, the two probes representing PRMT2
(HRMT1L1.gff2216_a and HRMT1L1.gff2216_b) belonged
to classes IV and III, respectively. This difference could
also be explained by the existence of two alternative tran-
scripts containing either exons 5/6 or exons 8/9 described
in the ENSEMBL database.
QPCR Validation Experiments
To conﬁrm variations in gene expression and to validate
the classiﬁcation of chromosome 21 genes, we performed
QPCR on 11 genes belonging to class I (1 gene), class II
(2 genes), class III (6 genes), and class IV (2 genes). QPCR
was conducted on all LCLs from individuals with DS and
control individuals. Ratios obtained by QPCR conﬁrmed
the classiﬁcation of chromosome 21 genes deduced from
HSA21 oligoarrays, except for SOD1. SOD1 belonged to
class III and had a ratio of 1.57 by QPCR. However, this
1.57-fold difference between LCLs from individuals with
DS and control individuals was not signiﬁcant ( ).Pp .15
DS/control ratios from QPCR were in agreement with ra-
tios obtained from HSA21 oligoarrays (table 6), with a cor-
relation coefﬁcient of 0.82. Our HSA21 oligoarraywas thus
a comprehensive, reproducible, and sensitive tool for
studying gene expression in DS.
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Table 6. Comparison between QPCR Results and Microarray
Data
HSA21
Gene
GenBank
Accession
Number
Data from
HSA21 Oligoarray
DS/Control
Ratio by QPCRa
DS/Control
Ratiob Class
SNF1LK AB047786.1 2.14 II 3.36
STCH U04735.1 1.97 II 2.06
MX1 AF135187.1 1.49 IV 1.78
DYRK1A D86550.1 1.41 I 1.77
CSTB AF208234.1 1.35 IV 1.49
CHAF1B U20980.1 1.29 III 1.38
TMEM1 BC101728.1 1.27 III 1.27
GART X54199.1 1.17 III 1.38
SOD1 AY835629.1 1.15 III 1.57
H2BFS AB041017.1 1.13 III 1.05
DSCR1 AY325903.1 .93 III 1.11
a The mean expression ratio for the corresponding gene between DS
and control cell lines.
b DS/control ratio by QPCR was calculated from normalized Ct obtained
for DS cell lines relative to control cell lines.
Figure 3. PCA of HSA21 genes (A) and non-HSA21 genes (B). Red and blue symbols represent DS and control samples, respectively.
Squares represent samples extracted from females, and diamonds represent samples extracted from males.
Discussion
The aim of the study was to analyze chromosome 21 gene
expression in LCLs from individuals with DS and control
individuals. Forty differential hybridizations comparing
DS LCLs with control LCLs were performed on a dedicated
HSA21 oligoarray designed from the complete human
chromosome 21 gene catalogue (359 genes). Approxi-
mately one-third (134) of all chromosome 21 genes, ORFs,
and predictions were expressed in LCLs.
On the basis of the expression levels of chromosome 21
genes, DS samples were clearly distinct from control sam-
ples, thus reﬂecting the prevalent effect of DS on chro-
mosome 21 gene expression. On the contrary, reference
genes mapping to chromosomes other than 21 could not
distinguish DS LCLs from control LCLs. Using the mixed-
model analysis, we were able to detect genes that are sig-
niﬁcantly overexpressed in DS cell lines (58) and also
genes that deviate from the gene-dosage effect, with DS/
control expression ratios signiﬁcantly different from 1.5.
Classiﬁcation of HSA21 Genes
By use of this new data analysis protocol, human chro-
mosome 21 genes can now be ranked into four classes by
their expression levels in DS cell lines relative to controls.
This protocol could be applied to expression data obtained
from other human tissues, to validate the classiﬁcation.
Class I contains 30 genes with expression ratio of DS/
control close to 1.5 (range 1.3–1.67), correlated to the pres-
ence of three genomic copies (table 4 and ﬁg. 1). These
class I genes could be responsible for the phenotype ob-
served in DS, either directly or indirectly through a sec-
ondary effect of cis- or trans-acting genes.
Class II contains nine genes with expression ratio of DS/
control 11.64, corresponding to an ampliﬁcation of the
initial gene dosage (table 4 and ﬁg. 1). Among these genes,
SAMSN1, SNF1LK, STCH, and BTG3 show the highest ex-
pression ratio, in the range 1.67–2.27.
Gene-dosage ampliﬁcation could result from a cascad-
ing effect through regulation networks involving trans- or
cis-acting genes.35 Pellegrini et al.36 identiﬁed in silico a
putative mitogen-activated kinase cascade with chromo-
some 21 kinases involved in various signaling pathways:
DYRK1A, SNF1LK, RIPK4, and DSCR3. In our study,
DYRK1A, SNF1LK, and DSCR3 were expressed in LCLs,
whereas RIPK4 was not. Thus, four replicates were chosen
for each patient.
DYRK1A is under the gene-dosage effect and DSCR3 is
compensated, whereas SNF1LK is ampliﬁed from the ini-
tial gene dosage. On the basis of this putative mitogen-
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Figure 4. Distribution of the variance of M for class I, II, III,
and IV genes. The plot represents the minimum and maximum
values (whiskers), the ﬁrst and third quartiles (box), and the me-
dian value (midline) of the variances of M for each class of genes,
where M is the mean of .log (DS) log (control)2 2
activated kinase cascade, ampliﬁcation of SNF1LK gene
expression could thus result from the overexpression of
DYRK1A acting as a regulatory factor on SNF1LK in the
cascade, and DSCR3 could act as a scaffolding protein.
Class III is the most abundant and contains 77 genes,
with a large proportion of gene predictions and antisense
transcripts with DS/control expression ratio !1.4 (table 4
and ﬁg. 1). These class III genes are likely to be compen-
sated in DS. Compensation mechanisms in trisomic con-
ditions have been described in maize and Drosophila37–39
and have been suggested in previous transcriptome stud-
ies, both in patients with DS10,12,16 and in mouse mod-
els.4,19–21 For example, Lyle et al.20 found that 45% of the
triplicated genes analyzed in their study were compen-
sated. Compensation is most likely due to negative feed-
backs that would modulate transcriptional activity or
mRNA stability of class III genes. Thus, expression of com-
pensated genes could be regulated by mechanisms that
are not impaired in DS. For example, trans-inhibitorscould
act directly on the level of expression of these genes. Al-
ternatively, trans-activators would activate inhibitors pre-
sent in three copies on chromosome 21 and would reduce
the expression level of target genes that could be also be
present on chromosome 21.40 However, the existence of
polymorph alleles correlated to different levels of expres-
sion should not account for either gene compensation or
ampliﬁcation in a representative population of patients
with DS. A recent study has demonstrated that two CpG
islands from human chromosome 21 can be methylated
monoallelically.41 One of those maps to DSCR3, the other
to C21orf29. Both are class III genes in LCLs.
Six class III genes were tested by QPCR, and all were
validated, except SOD1. SOD1 is a well-characterized gene
that has been shown elsewhere to be overexpressed in DS
tissues and cells at the RNA and protein levels.13,16,42 In
LCLs, the SOD1 gene is transcribed into two variants, a
long and a short isoform.43 Since SOD1 probes from the
HSA21 oligoarray mapped to the long isoform only, the
classiﬁcation (class III compensated) (table 5) corre-
sponded to this long isoform. The ratio deduced from the
HSA21 oligoarray (1.15) was found to be slightly lower
than the one obtained by QPCR for the long isoform
(1.57). However, by use of QPCR primers amplifying both
isoforms of SOD1, with the short isoform the most abun-
dant in LCLs, we found that the ratio between DS and
control LCLs was 1.96 (data not shown). These results sug-
gest that, in DS LCLs, SOD1 is overexpressed.
Class IV contains 15 genes and 5 gene predictions that
have DS/control expression ratio not different from either
1 or 1.5. These class IV genes are thus highly variable
between individuals with DS and control individuals. In-
deed, ﬁgure 4 shows that the variance distribution of
expression ratios is the highest for class IV genes. Three
class IV genes (CBR1, PRDM15, and ADARB1) were
shown elsewhere to be highly variable among unaffected
individuals.44
Using the mixed-model analysis, we have been able to
distinguish between gene expression differences resulting
from DS and those from interindividual variations. In-
terindividual variations have been assessed in normal
LCLs.45–47 In the present study, we used lymphoblastoid
cells established from individuals with DS and control in-
dividuals all belonging to Indo-European populations,
thus limiting the variations due to ethnic groups.
Copy-number variations have also been described in
LCLs.48 They should not have an impact on the results
unless their frequencies are different in individuals with
DS and control individuals, which is unlikely. Moreover,
we could not ﬁnd any correlation between the type of
copy-number variation (gain or loss) described for partic-
ular genes and their gene class. For example, two genes
mapping to the same copy-number variant (variation
516248) belonged to class II (PDXK) and class IV (CSTB).
Comparison with Expression Data Obtained from DS Tissues
Mao et al.16 studied transcriptome modiﬁcations in DS
fetal heart, cerebellum, and astrocyte cells, using a pan-
genomic Affymetrix U133A chip. Of the 200 genes as-
signed to HSA21, 23 were signiﬁcantly changed in DS tis-
sues and 17 were in common with the 58 HSA21 genes
that were signiﬁcantly changed in our study. Our results
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Figure 5. Distribution of expressed, class I, II, III, and IV genes along HSA21. The left Y-axis indicates the proportion of expressed
genes in each 5-Mb interval, and the right Y-axis indicates the proportion of class I, II, III, and IV genes in each 5-Mb interval.
are also in agreement with another gene-expression study
performed on DS fetal heart cells17 that showed that 16
HSA21 genes are signiﬁcantly overexpressed in fetal
hearts. Among these 16 genes, 8 were signiﬁcantly
changed in our study. Class I, II, and III genes were present
in all tissues, suggesting that gene-dosage effect, ampliﬁ-
cation, and compensation are general phenomena and
that LCLs are a good model for studying gene-dosage ef-
fects. The differences observed between our study and the
others suggest tissue-speciﬁc regulations that have been
described elsewhere for the control ofGABPa expression.49
Distribution of Gene-Expression Modiﬁcations along HSA21
We have analyzed the distribution of expressed genes, as
well as individual gene classes along HSA21. Figure 5
shows that expressed genesmap preferentially to the distal
part of HSA21, reﬂecting the nonuniform gene density
along HSA21q.27 The most telomeric region of HSA21 has
a high proportion of class III genes, perhaps because of
the presence of a higher proportion of gene predictions
that are localized inside gene introns.
DS Effects on Alternative Transcripts
To search for differential effects of DS on alternatively
spliced transcripts, we analyzed genes for which oligo-
nucleotide probes present on the HSA21 oligoarray could
differentiate between alternative transcripts. Seventeen
genes had probes speciﬁc to alternative transcripts (table
7). For seven of those genes, all the probes gave a very
low signal, indicating that these transcripts are not ex-
pressed in LCLs. Three genes (C21orf33, C21orf34, and
MRPL39) were expressed in LCLs as a unique transcript
and belonged to class I genes, which are overexpressed
with a ratio close to 1.5. For the last seven genes (ADARB1,
C21orf66, DYRK1A, GART, PKNOX1, RUNX1, andTMEM1),
oligonucleotide probes could distinguish between splicing
variants that had very similar DS/control ratios. Only two
of these genes (C21orf66 and DYRK1A) were signiﬁcantly
overexpressed in DS LCLs (i.e., were class I genes), whereas
the others were compensated. These results suggest that
most of the transcripts belonging to the same gene and
expressed in LCLs are similarly regulated in DS.
DS Effects on Antisense Transcripts
The HSA21 oligoarray was also designed to analyze the
effects of DS on the expression of antisense transcripts.
Fourteen antisense transcripts are present with their nest-
ing genes on the HSA21 oligoarray (table 8). Among them,
10 have been extracted from the HSA21 database estab-
lished by Kathleen Gardiner at the Eleanor Roosevelt In-
stitute.50 The four remaining antisense transcripts corre-
sponded to transcribed sequences in the DCR that have
been generated from various cDNA mapping and exon-
trapping experiments.8,51,52 Seven genes (C21orf25, CHAF1B,
DYRK1A, HLCS, KIAA0179, MCM3AP, and TTC3) are ex-
pressed in LCLs. Four of the corresponding antisense tran-
scripts (as-DYRK1A, as-HLCS, as-KIAA0179, and as-TTC3)
were also found to be expressed in LCLs, thus conﬁrming
Table 7. Alternative Transcripts of HSA21 Genes
Gene Symbol and Probe
GenBank
Accession
Number A
DS/Control
Ratio M Var(M)
Recognized
Variantsa Class
ADARB1:
ADARB1.alt23565_a AY135659.1 5.23 NE NE NE 1, 2, 3, 4 NE
ADARB1.alt23565_b AY135659.1 4.89 NE NE NE 1, 2, 3, 4 NE
ADARB1.alt3788_a AY135659.1 7.36 1.22 .29 2.69 1, 2, 4 IV
ADARB1.alt3788_b AY135659.1 7.21 1.3 .38 3.46 1, 2, 4 IV
C21orf33:
HES1.gff1583_b BC003587.1 5.46 NE NE NE 1 NE
bi824121 BI824121.1 10.2 1.5 .58 .16 1, 2 I
HES1.gff1583_a BC003587.1 10.86 1.53 .62 .25 1, 2 I
C21orf34:
orf3435.eri594_a AF486622.1 5.5 NE NE NE 1 NE
C21orf34.gff397_a AF486622.1 5.87 NE NE NE 1, 2 NE
C21orf34.gff397_b AF486622.1 5.83 NE NE NE 1, 2 NE
orf3435.alt629_b AF486622.1 6.15 NE NE NE 1, 2 NE
orf3435.eri594_b AF486622.1 5.69 NE NE NE 1, 2 NE
C21orf35.gff251_a AF486622.1 5.95 NE NE NE 1, 2, 3 NE
orf3435.alt2559_a AF486622.1 8.15 .95 .07 .30 1, 2, 3 III
orf3435.alt629_a AF486622.1 8.2 .9 .15 .27 1, 2, 3 III
C21orf66:
B3GCFC.eri2361_a AY033903.1 5 NE NE NE 1, 2, 3 NE
B3GCFC.eri2361_b AY033903.1 5.48 NE NE NE 1, 2, 3, 4 NE
GCFC.eri2361_a AY033903.1 10.6 1.56 .64 .09 1, 2, 3 I
GCFC.eri2361_b AY033903.1 8.93 1.51 .6 .04 1, 2, 3, 4 I
GCFC.gff1083_a AY033903.1 10.19 1.48 .57 .22 1, 2, 3 I
GCFC.gff1083_b AY033903.1 8.29 1.47 .56 .12 1, 2, 3 I
DYRK1A:
DYRK1.alt2571_a D86550.1 10.33 1.4 .48 .13 1, 2, 3, 4, 5 I
DYRK1.alt2571_b D86550.1 10.71 1.4 .49 .22 1, 2, 3, 4, 5 I
DYRK1.gff5318_a D86550.1 9.47 1.41 .5 .19 1, 2, 3, 4, 5 I
DYRK1.gff5318_b D86550.1 11.02 1.41 .5 .22 1, 2, 3, 4, 5 I
GART:
GART.gff3271_a X54199.1 8.79 1.18 .24 .10 1 III
GART.gff3271_b X54199.1 10.35 1.17 .22 .20 1, 2 III
MRPL39:
PRED22.eri707_a AF109357.1 9.46 1.41 .5 .14 1, 2 I
PRED22.eri707_b AF109357.1 10.56 1.47 .55 .17 1, 2 I
PRED22.gff1072_a AF109357.1 10.33 1.47 .56 .13 1, 2 I
PRED22.gff1072_b AF109357.1 10.33 1.46 .55 .18 1, 2 I
PRED66.eri187_a AF109357.1 10.28 1.51 .6 .12 1, 2 I
PRED66.eri187_b AF109357.1 9.36 1.51 .59 .16 1, 2 I
PRED66.gff641_b AF109357.1 8.31 1.42 .5 .17 1, 2 I
PRED66.gff641_a AF270511.1 6.58 NE NE NE 2 NE
PKNOX1:
PKNOX1.gff3279_a AY196965.1 7.64 1.05 .07 .11 1 III
PKNOX1.gff3279_b AY196965.1 7.98 1.03 .04 .14 1, 2 III
RUNX1:
RUNX1.alt25714_a D43968.1 7.23 .86 .21 .84 1, 2 III
RUNX1.alt7267_a D43968.1 7.37 .8 .32 .74 1, 2 III
RUNX1.alt7267_b D43968.1 5.56 NE NE NE 2 NE
RUNX1.gff2722_a D43968.1 7.92 .85 .23 .74 2 III
RUNX1.gff2722_b D43968.1 9.03 .89 .17 .76 2 III
TMEM1:
TMEM1.gff5126_a BC101728.1 10.53 1.25 .32 .14 1 III
TMEM1.gff5126_b BC101728.1 10.5 1.28 .36 .14 1, 2 III
NOTE.—The value A corresponds to for the corresponding gene across the 40 hybridizations,[log (DS) log (control)]/22 2
M corresponds to the mean of for the corresponding gene across the 40 hybridizations,log (DS) log (control)2 2
is the variance of M, and the DS/control ratio is equal to 2M. NE p not expressed.Var (M)
a The number of transcript variants hybridizing to the oligonucleotide probe.
Table 8. Sense and Antisense Transcripts on Chromosome 21
Gene Symbol and Probe
GenBank
Accession
Number
Intragenic
Locationa A M Var(M)
DS/Control
Ratio Class
C21orf56:
C21orf56.gff691_a BC084577.1 Exon 2 5.51 NE NE NE NE
as-C21orf56:
C21orf56.gff284_a BC084577.1 Exon 4 10.68 .12 .08 1.08 III
C21orf56.gff284_b BC084577.1 Exon 4 12.79 .08 .08 1.05 III
CHAF1B:
CHAF1B.gff2194_a U20980.1 Exon 14 8.66 .37 .12 1.29 III
CHAF1B.gff2194_b U20980.1 Exon 14 8.03 .38 .14 1.30 III
as-CHAF1B:
BF740066 BF740066.1 3′ 5.08 NE NE NE NE
HLCS:
HLCS.gff6722_a AB063285.1 Exon 12 6.37 NE NE NE NE
HLCS.gff6722_b AB063285.1 Exon 11 8.48 .40 .18 1.32 III
as-HLCS:
DCR1-8.0_a AJ001862.1 Intron 7 7.58 .03 .42 .98 III
DCR1-8.0_b AJ001862.1 Intron 7 5.83 NE NE NE NE
TTC3:
TTC3.gff9074_a D84296.1 Exon 47 10.02 .84 .23 1.79 II
TTC3.gff9074_b D84296.1 Exon 34 11.17 .83 .17 1.78 II
as-TTC3:
bf979681 BF979681.2 Exon 41 9.07 .64 .64 1.56 I
DYRK1A:
DYRK1.alt2571_a D86550.1 Exon 13 10.33 .48 .13 1.40 I
DYRK1.alt2571_b D86550.1 Exons 7/8 10.71 .49 .22 1.40 I
DYRK1.gff5318_a D86550.1 Exon 13 9.47 .50 .11 1.41 I
DYRK1.gff5318_b D86550.1 Exon 11 11.02 .50 .22 1.41 I
as-DYRK1A:
DCR1-12.0_a AJ001868.1 Intron 1 7.37 .36 .76 1.29 IV
DCR1-13.0-RC_a AJ001869.1 Intron 1 8.33 .15 .95 1.11 IV
DCR1-13.0-RC_b AJ001869.1 Intron 1 9.55 .22 .91 1.17 IV
KCNJ6:
GIRK2(U52153)_a U52153.1 Exon 3 5.60 NE NE NE NE
GIRK2(U52153)_b U52153.1 Exon 1 5.28 NE NE NE NE
as-KCNJ6:
DCR1-17DCR1-17_a AJ001875.1 Intron 3 7.16 .17 .70 1.12 IV
ADAMTS5:
ADAMTS5.gff5523_a AF142099.1 Exon 8 5.39 NE NE NE NE
ADAMTS5.gff5523_b AF142099.1 Exon 8 5.39 NE NE NE NE
as-ADAMTS5:
r18879 R18879.1 Intron 3 5.69 NE NE NE NE
as-C21orf25:
aa575913 AA575913.1 3′ 5.85 NE NE NE NE
C21orf25:
C21orf25.gff6217_a AB047784.1 Exon 14 8.96 .17 .45 1.13 III
C21orf25.gff6217_b AB047784.1 Exon 14 8.24 .32 .17 1.25 III
as-CBR3:
bi836686 BI836686.1 Exon 3 5.90 NE NE NE NE
CBR3:
CBR3.gff878_a AB124847.1 Exon 3 6.18 NE NE NE NE
CBR3.gff878_b AB124847.1 Exons 1/2 5.31 NE NE NE NE
CLDN14:
CLDN14.gff1693_a AF314090.1 Exon 3 6.78 NE NE NE NE
CLDN14.gff1693_b AP001726.1 3′ 6.05 NE NE NE NE
as-CLDN14:
w90592 W90592.1 3′ 5.71 NE NE NE NE
KIAA0179:
KIAA0179.gff4984_a D80001.1 Exon 16 5.26 NE NE NE NE
KIAA0179.gff4984_b D80001.1 Exon 16 10.15 .28 .24 1.22 III
as-KIAA0179:
aa425659 AA425659.1 3′ 8.08 .22 .67 1.17 III
MCM3AP:
MCM3.gff6113_a AY590469.1 Exon 27 11.69 .54 .19 1.45 I
MCM3APAS:
af426262 AF426262.1 Introns 25–26 5.54 NE NE NE NE
af426263 AF426263.1 Introns 20–21 5.73 NE NE NE NE
NOTE—The value A corresponds to for the corresponding gene across the 40 hybridizations,[log (DS) log (control)]/22 2
M corresponds to the mean of for the corresponding gene across the 40 hybridizations,log (DS) log (control)2 2
is the variance of M, and the DS/control ratio is equal to 2M. NE p not expressed.Var (M)
a The exon or intron to which the oligonucleotide probe maps.
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their existence. TTC3 (class II) and its antisense transcript
(class I) were overexpressed, whereas the other antisense
sequences did not belong to the same class as their cor-
responding genes. In addition, two antisense sequences
(as-C21orf56 and as-KCNJ6) were expressed in LCLs,
whereas their corresponding genes were not. The probe
referred to as antisense transcript as-KCNJ6 mapping in
intron 3 of KCNJ6, on the opposite strand, corresponds
to one of the transcribed sequences isolated in the DCR
by exon-trapping experiments.8 Since there is no evidence
that this sequence is an antisense transcript of KCNJ6, it
could thus belong to a gene locus that has not yet been
identiﬁed and might map to the opposite orientation of
KCNJ6.
According to the NCBI Gene Database, C21orf56 (ac-
cession number 84221) currently maps on the negative
strand of HSA21 but was previously annotated on the pos-
itive strand when the HSA21 oligoarray was designed.
Thus, probe sequence representing the antisense tran-
script as-C21orf56 could correspond to the actual sense
transcript of C21orf56. Therefore, the expression of anti-
sense transcripts is conﬁrmed by our HSA21 oligoarray
experiments. Sense and antisense transcripts are not al-
ways similarly changed in DS.
In conclusion, using our new high-content HSA21 oli-
goarrays combined with a new powerful statistical analysis
protocol, we were able to classify HSA21 genes according
to their level of expression in DS LCLs. We show that,
among the expressed transcripts, 29% are sensitive to the
gene-dosage effect or are ampliﬁed, 56% are compensated,
and 15% are highly variable among individuals. Thus,
most of the chromosome 21 genes are compensated for
the gene-dosage effect. Gene-expression variations in DS
are controlled by mechanisms involving trans and cis reg-
ulators acting either directly or through gene-regulation
networks. Overexpressed genes are likely to be involved
in the DS phenotype, in contrast to the compensated
genes. Highly variable genes could account for phenotypic
variations observed in patients. Finally, we show that al-
ternative transcripts belonging to the same gene are sim-
ilarly regulated in DS, whereas sense and antisense tran-
scripts are not always similarly regulated. Studies of
human tissues by use of the same analysis protocol will
validate genes that are involved in the DS phenotype.
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